Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open randomized phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in high grade prostate cancer patients with margin positive T2 or T3 tumours

Next Previous
X
Search
Trial Profile

An open randomized phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in high grade prostate cancer patients with margin positive T2 or T3 tumours

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms AdPro

    • Most Recent Events

    • 26 Aug 2013 Biomarkers information updated
    • 08 Nov 2012 Planned number of patients changed from 396 to 460.
    • 08 May 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top